Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy
In the POTOMAC trial, one year of Imfinzi plus BCG reduced disease recurrence, progression or death risk by 32%. Credit: Sai Thaw Kyar / Shutterstock.com.
In the POTOMAC trial, one year of Imfinzi plus BCG reduced disease recurrence, progression or death risk by 32%. Credit: Sai Thaw Kyar / Shutterstock.com.